Loading...
Market
What will be the primary reason for patients discontinuing Susvimo eye implant by the end of 2024?
2
Resolution / Starting Odds
Adverse events • 25%
Lack of efficacy • 25%
Cost • 25%
Other • 25%
Genentech patient surveys and medical reports
Story
Genentech, Roche Unit, Reintroduces Susvimo Eye Implant After Recall
Jul 8, 2024, 07:24 PM
Genentech, a unit of Roche Group, has announced the reintroduction of its eye implant, Susvimo, in the United States. The implant is designed for people with wet age-related macular degeneration (AMD), a blinding eye disease. The re-launch follows the end of a voluntary recall that took place two years ago. Susvimo, which was recalled, is a refillable implant, and it will be available to patients in the coming weeks. The announcement was made on Monday.
View original story
Similar markets
0-10 patients • 25%
11-20 patients • 25%
21-30 patients • 25%
More than 30 patients • 25%
0-25% • 25%
26-50% • 25%
51-75% • 25%
76-100% • 25%
Age-related macular degeneration • 25%
Diabetic retinopathy • 25%
Retinitis pigmentosa • 25%
No other application • 25%
Yes • 50%
No • 50%
0-5 patients • 25%
6-10 patients • 25%
11-15 patients • 25%
More than 15 patients • 25%
Amgen • 25%
Regeneron • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Below 80% • 25%
80% to 85% • 25%
85% to 90% • 25%
Above 90% • 25%
Confirms significant risk • 25%
No significant risk found • 25%
Inconclusive results • 25%
Study retracted • 25%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
Yes • 50%
No • 50%
Revenue decrease due to MRT-6160 • 25%
Revenue increase due to MRT-6160 • 25%
No significant financial impact • 25%
MRT-6160 discontinued • 25%